Novel approach for real-time monitoring of carrier-based DPIs delivery process
ACI, Anderson Cascade Impactor
APIs, active pharmaceutical ingredients
Air flow rate
CFD-DEM, computational fluid dynamics-discrete element method
CIA, cascade impactor analysis
Carrier
Copt, optical concentration
DPIs, dry powder inhalations
Dry powder inhalation
ED, emitted dose
EDXS, energy-dispersive X-ray spectroscopy
FC, centrifugal force
FD, drag force
FF, friction force
FG, gravity
FI, interaction force
FPD, fine particle dose
FPF, fine particle fraction
HPLC, high performance liquid chromatography
HPMC, hydroxy propyl methyl cellulose
LAC, lactose carrier
MFV, minimum fluidization velocity
MMAD, mass median aerodynamic diameter
MMSH, modular modified Sympatec HELOs
MOC, micro orifice collector
MSS, micronized salbutamol sulfate
Mechanism of drug delivery
Modular modification
NGI, Next Generation Impactor
O, oxygen
PDP, pulmonary delivery process
Pulmonary delivery process
R, release amount
RAUC, total release amount
Real-time monitoring
Rmax, maximum of release amount
S, stopping distance
SEM, scanning electron microscope
Tmax, the time to Rmax
Tt, terminal time
U0, air flow rate
V0, velocity
a, acceleration
dQ3, the volume percentage of particles within certain range
dae, aerodynamic diameter
Journal
Acta pharmaceutica Sinica. B
ISSN: 2211-3835
Titre abrégé: Acta Pharm Sin B
Pays: Netherlands
ID NLM: 101600560
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
06
12
2019
revised:
12
02
2020
accepted:
18
02
2020
entrez:
3
9
2020
pubmed:
3
9
2020
medline:
3
9
2020
Statut:
ppublish
Résumé
An explicit illustration of pulmonary delivery processes (PDPs) was a prerequisite for the formulation design and optimization of carrier-based DPIs. However, the current evaluation approaches for DPIs could not provide precise investigation of each PDP separately, or the approaches merely used a simplified and idealized model. In the present study, a novel modular modified Sympatec HELOS (MMSH) was developed to fully investigate the mechanism of each PDP separately in real-time. An inhaler device, artificial throat and pre-separator were separately integrated with a Sympatec HELOS. The dispersion and fluidization, transportation, detachment and deposition processes of pulmonary delivery for model DPIs were explored under different flow rates. Moreover, time-sliced measurements were used to monitor the PDPs in real-time. The Next Generation Impactor (NGI) was applied to determine the aerosolization performance of the model DPIs. The release profiles of the drug particles, drug aggregations and carriers were obtained by MMSH in real-time. Each PDP of the DPIs was analyzed in detail. Moreover, a positive correlation was established between the total release amount of drug particles and the fine particle fraction (FPF) values (
Identifiants
pubmed: 32874832
doi: 10.1016/j.apsb.2020.02.013
pii: S2211-3835(19)31710-1
pmc: PMC7452036
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1331-1346Informations de copyright
© 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
Références
AAPS J. 2013 Apr;15(2):511-22
pubmed: 23371759
AAPS J. 2016 Sep;18(5):1159-1167
pubmed: 27161214
Res Pharm Sci. 2018 Jun;13(3):283-287
pubmed: 29853937
Annu Rev Physiol. 2013;75:593-615
pubmed: 23398155
Expert Opin Drug Deliv. 2018 May;15(5):443-457
pubmed: 29532682
Int J Pharm. 2017 Sep 15;530(1-2):30-39
pubmed: 28709940
Pharm Res. 2011 May;28(5):1157-66
pubmed: 21287249
Drug Dev Ind Pharm. 2019 Oct;45(10):1664-1673
pubmed: 31389270
AAPS J. 2015 Nov;17(6):1407-16
pubmed: 26201967
Adv Drug Deliv Rev. 2012 Mar 15;64(3):257-74
pubmed: 21565232
Pharm Res. 2004 Sep;21(9):1591-7
pubmed: 15497684
Int J Pharm X. 2019 May 30;1:100018
pubmed: 31517283
Conf Proc IEEE Eng Med Biol Soc. 2013;2013:6866-9
pubmed: 24111322
Drug Dev Ind Pharm. 2017 Dec;43(12):2085-2091
pubmed: 28831840
Eur J Pharm Sci. 2019 Feb 1;128:299-324
pubmed: 30553814
Mater Sci Eng C Mater Biol Appl. 2014 May 1;38:1-10
pubmed: 24656346
Int J Pharm. 2018 Mar 1;538(1-2):30-39
pubmed: 29289516
Int J Pharm. 2018 Apr 25;541(1-2):143-156
pubmed: 29454905
Pharm Res. 2005 Sep;22(9):1445-53
pubmed: 16132356
Acta Pharm Sin B. 2014 Feb;4(1):52-9
pubmed: 26579364
Expert Opin Drug Deliv. 2004 Nov;1(1):67-86
pubmed: 16296721
J Control Release. 2019 Nov 28;314:62-71
pubmed: 31654686
Eur J Pharm Biopharm. 2014 Sep;88(1):148-52
pubmed: 24780441
Int J Pharm. 2019 Apr 20;561:148-160
pubmed: 30825556
Ann Am Thorac Soc. 2017 Jul;14(7):1103-1107
pubmed: 28481631
Adv Drug Deliv Rev. 2014 Aug;75:32-52
pubmed: 24735676
Curr Pharm Des. 2015;21(40):5900-14
pubmed: 26446471
Drug Dev Ind Pharm. 2015;41(9):1431-7
pubmed: 25220930
J Aerosol Med Pulm Drug Deliv. 2010 Dec;23(6):363-9
pubmed: 20863250
Eur J Pharm Biopharm. 2010 Nov;76(3):464-9
pubmed: 20854906
Pharm Res. 2017 Mar;34(3):507-528
pubmed: 27738953
J Aerosol Med Pulm Drug Deliv. 2018 Apr;31(2):116-118
pubmed: 29596020
Expert Opin Drug Deliv. 2015 Jun;12(6):947-62
pubmed: 25388926
J Control Release. 2019 Nov 28;314:102-115
pubmed: 31629037
J Allergy Clin Immunol Pract. 2020 Mar;8(3):1124-1125.e4
pubmed: 31593777
Acta Pharm Sin B. 2018 May;8(3):440-448
pubmed: 29881683
Int J Pharm. 2018 Jan 30;536(1):326-335
pubmed: 29217472
Adv Drug Deliv Rev. 2014 Aug;75:18-31
pubmed: 24735675
AAPS PharmSciTech. 2017 Nov;18(8):2862-2870
pubmed: 28421352
Drugs. 2015 Sep;75(14):1679-86
pubmed: 26384673
Eur J Pharm Biopharm. 2014 Jan;86(1):105-14
pubmed: 24140941
P T. 2014 Sep;39(9):621-3, 648
pubmed: 25210413
Sci Rep. 2017 May 02;7:46517
pubmed: 28462948
Einstein (Sao Paulo). 2019 May 2;17(2):eAO4397
pubmed: 31066791
Int J Pharm. 2002 Dec 5;249(1-2):233-45
pubmed: 12433451
Pharm Res. 2012 Jul;29(7):1797-807
pubmed: 22327971
Int J Pharm. 2016 Dec 5;514(2):445-455
pubmed: 27497998
J Aerosol Med. 2003 Fall;16(3):283-99
pubmed: 14572326
AAPS PharmSciTech. 2019 Jul 8;20(6):249
pubmed: 31286316
AAPS PharmSciTech. 2014 Aug;15(4):898-909
pubmed: 24756910